MiR-126 plays anti-angiogenic role in BC through negative regulation of VEGFA/PI3K/ERK via direct targeting VEGFA and phosphoinositide-3-kinase regulatory subunit 2 (PI3KR2/p85-β) [77]. This evidence concerns the gene PIK3R2 and breast cancer.